FOXP3 and myeloid sarcoma: The upregulation of FoxP3 in peripheral blood mononuclear cells was found to be more pronounced 6 months after intrathecal injection of MSC in almost all subjects, indicating an increased regulatory T cell activity that could play a role in the clinical stability of MS patients (Mohajeri et al., 2011).